Publication

Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH)

ter Avest, E., Abbink, E. J., Holewijn, S., de Graaf, J., Tack, C. J. & Stalenhoef, A. F. H., Sep-2005, In : Current Medical Research and Opinion. 21, 9, p. 1469-1476 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

ter Avest, E., Abbink, E. J., Holewijn, S., de Graaf, J., Tack, C. J., & Stalenhoef, A. F. H. (2005). Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Current Medical Research and Opinion, 21(9), 1469-1476. https://doi.org/10.1185/030079905X61910

Author

ter Avest, Ewoud ; Abbink, Evertine J ; Holewijn, Suzanne ; de Graaf, Jacqueline ; Tack, Cees J ; Stalenhoef, Anton F H. / Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). In: Current Medical Research and Opinion. 2005 ; Vol. 21, No. 9. pp. 1469-1476.

Harvard

ter Avest, E, Abbink, EJ, Holewijn, S, de Graaf, J, Tack, CJ & Stalenhoef, AFH 2005, 'Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH)' Current Medical Research and Opinion, vol. 21, no. 9, pp. 1469-1476. https://doi.org/10.1185/030079905X61910

Standard

Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). / ter Avest, Ewoud; Abbink, Evertine J; Holewijn, Suzanne; de Graaf, Jacqueline; Tack, Cees J; Stalenhoef, Anton F H.

In: Current Medical Research and Opinion, Vol. 21, No. 9, 09.2005, p. 1469-1476.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

ter Avest E, Abbink EJ, Holewijn S, de Graaf J, Tack CJ, Stalenhoef AFH. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Current Medical Research and Opinion. 2005 Sep;21(9):1469-1476. https://doi.org/10.1185/030079905X61910


BibTeX

@article{dca154852c604624b992054d9eb0ebd6,
title = "Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH)",
abstract = "OBJECTIVE: Although several studies have reported a positive effect of statins on endothelial vasoreactivity, most studies performed in subjects with type 2 diabetes mellitus report no effect at all. This lack of effect may be related to the existence of insulin resistance, or to insufficient lowering of atherogenic (apo)lipoproteins. Therefore, we tested in this study whether treatment of insulin resistant familial combined hyperlipidaemia (FCH) patients with a high dose (40 mg/day) of the potent rosuvastatin was able to improve endothelial function, without necessarily improving insulin sensitivity.RESEARCH DESIGN AND METHODS: In a double-blind randomised crossover study, 18 subjects with FCH (without evident cardiovascular disease, mean [standard deviation] age 54 [7] years) underwent a 4-week run-in period after which they were randomised to treatment with placebo once daily for 12 weeks, followed by rosuvastatin 40 mg/day for 12 weeks or vice versa. Endothelial function was determined after 8 and 12 weeks of both treatment periods, respectively, by measurement of flow-mediated vasodilation (FMD) using high-resolution ultrasound and by measurement of vasodilator response to intrabrachial acetylcholine (Ach) by venous occlusion plethysmography (forearm blood flow [FBF]).RESULTS: Plasma levels of lipids, (apo)lipoproteins and high-sensitivity C-reactive protein (hsCRP) improved significantly after rosuvastatin therapy compared to placebo. However, rosuvastatin had no effect on homeostasis model assessment (HOMA)-indices or on vasodilator responses to intra-brachial acetylcholine-infusion (FBF-ratio increased from a mean of 1.28 [SD: 0.46] to 5.82 [3.44] after rosuvastatin and from 1.33 [0.67] to 5.99 [3.89] after placebo, p = 0.35). Endothelium-dependent FMD was also unchanged (1.6{\%} [3.1{\%}] vs. 3.2{\%} [3.5]{\%}, p = 0.56 rosuvastatin vs. placebo, respectively).CONCLUSION: In patients with FCH, a 12-week treatment of rosuvastatin 40 mg/day did not improve endothelial function (either in large conduit vessels or in resistance vessels), despite significant improvements in plasma lipids, (apo)lipoproteins. and low-grade inflammation.",
keywords = "Adult, Aged, Brachial Artery/diagnostic imaging, Cross-Over Studies, Diabetes Mellitus, Type 2/complications, Double-Blind Method, Endothelium, Vascular/diagnostic imaging, Female, Fluorobenzenes/pharmacology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology, Hyperlipidemia, Familial Combined/drug therapy, Insulin Resistance, Male, Middle Aged, Placebos, Plethysmography, Pyrimidines/pharmacology, Rosuvastatin Calcium, Sulfonamides/pharmacology, Treatment Outcome, Ultrasonography, Vasodilation",
author = "{ter Avest}, Ewoud and Abbink, {Evertine J} and Suzanne Holewijn and {de Graaf}, Jacqueline and Tack, {Cees J} and Stalenhoef, {Anton F H}",
year = "2005",
month = "9",
doi = "10.1185/030079905X61910",
language = "English",
volume = "21",
pages = "1469--1476",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Taylor & Francis Ltd",
number = "9",

}

RIS

TY - JOUR

T1 - Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH)

AU - ter Avest, Ewoud

AU - Abbink, Evertine J

AU - Holewijn, Suzanne

AU - de Graaf, Jacqueline

AU - Tack, Cees J

AU - Stalenhoef, Anton F H

PY - 2005/9

Y1 - 2005/9

N2 - OBJECTIVE: Although several studies have reported a positive effect of statins on endothelial vasoreactivity, most studies performed in subjects with type 2 diabetes mellitus report no effect at all. This lack of effect may be related to the existence of insulin resistance, or to insufficient lowering of atherogenic (apo)lipoproteins. Therefore, we tested in this study whether treatment of insulin resistant familial combined hyperlipidaemia (FCH) patients with a high dose (40 mg/day) of the potent rosuvastatin was able to improve endothelial function, without necessarily improving insulin sensitivity.RESEARCH DESIGN AND METHODS: In a double-blind randomised crossover study, 18 subjects with FCH (without evident cardiovascular disease, mean [standard deviation] age 54 [7] years) underwent a 4-week run-in period after which they were randomised to treatment with placebo once daily for 12 weeks, followed by rosuvastatin 40 mg/day for 12 weeks or vice versa. Endothelial function was determined after 8 and 12 weeks of both treatment periods, respectively, by measurement of flow-mediated vasodilation (FMD) using high-resolution ultrasound and by measurement of vasodilator response to intrabrachial acetylcholine (Ach) by venous occlusion plethysmography (forearm blood flow [FBF]).RESULTS: Plasma levels of lipids, (apo)lipoproteins and high-sensitivity C-reactive protein (hsCRP) improved significantly after rosuvastatin therapy compared to placebo. However, rosuvastatin had no effect on homeostasis model assessment (HOMA)-indices or on vasodilator responses to intra-brachial acetylcholine-infusion (FBF-ratio increased from a mean of 1.28 [SD: 0.46] to 5.82 [3.44] after rosuvastatin and from 1.33 [0.67] to 5.99 [3.89] after placebo, p = 0.35). Endothelium-dependent FMD was also unchanged (1.6% [3.1%] vs. 3.2% [3.5]%, p = 0.56 rosuvastatin vs. placebo, respectively).CONCLUSION: In patients with FCH, a 12-week treatment of rosuvastatin 40 mg/day did not improve endothelial function (either in large conduit vessels or in resistance vessels), despite significant improvements in plasma lipids, (apo)lipoproteins. and low-grade inflammation.

AB - OBJECTIVE: Although several studies have reported a positive effect of statins on endothelial vasoreactivity, most studies performed in subjects with type 2 diabetes mellitus report no effect at all. This lack of effect may be related to the existence of insulin resistance, or to insufficient lowering of atherogenic (apo)lipoproteins. Therefore, we tested in this study whether treatment of insulin resistant familial combined hyperlipidaemia (FCH) patients with a high dose (40 mg/day) of the potent rosuvastatin was able to improve endothelial function, without necessarily improving insulin sensitivity.RESEARCH DESIGN AND METHODS: In a double-blind randomised crossover study, 18 subjects with FCH (without evident cardiovascular disease, mean [standard deviation] age 54 [7] years) underwent a 4-week run-in period after which they were randomised to treatment with placebo once daily for 12 weeks, followed by rosuvastatin 40 mg/day for 12 weeks or vice versa. Endothelial function was determined after 8 and 12 weeks of both treatment periods, respectively, by measurement of flow-mediated vasodilation (FMD) using high-resolution ultrasound and by measurement of vasodilator response to intrabrachial acetylcholine (Ach) by venous occlusion plethysmography (forearm blood flow [FBF]).RESULTS: Plasma levels of lipids, (apo)lipoproteins and high-sensitivity C-reactive protein (hsCRP) improved significantly after rosuvastatin therapy compared to placebo. However, rosuvastatin had no effect on homeostasis model assessment (HOMA)-indices or on vasodilator responses to intra-brachial acetylcholine-infusion (FBF-ratio increased from a mean of 1.28 [SD: 0.46] to 5.82 [3.44] after rosuvastatin and from 1.33 [0.67] to 5.99 [3.89] after placebo, p = 0.35). Endothelium-dependent FMD was also unchanged (1.6% [3.1%] vs. 3.2% [3.5]%, p = 0.56 rosuvastatin vs. placebo, respectively).CONCLUSION: In patients with FCH, a 12-week treatment of rosuvastatin 40 mg/day did not improve endothelial function (either in large conduit vessels or in resistance vessels), despite significant improvements in plasma lipids, (apo)lipoproteins. and low-grade inflammation.

KW - Adult

KW - Aged

KW - Brachial Artery/diagnostic imaging

KW - Cross-Over Studies

KW - Diabetes Mellitus, Type 2/complications

KW - Double-Blind Method

KW - Endothelium, Vascular/diagnostic imaging

KW - Female

KW - Fluorobenzenes/pharmacology

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology

KW - Hyperlipidemia, Familial Combined/drug therapy

KW - Insulin Resistance

KW - Male

KW - Middle Aged

KW - Placebos

KW - Plethysmography

KW - Pyrimidines/pharmacology

KW - Rosuvastatin Calcium

KW - Sulfonamides/pharmacology

KW - Treatment Outcome

KW - Ultrasonography

KW - Vasodilation

U2 - 10.1185/030079905X61910

DO - 10.1185/030079905X61910

M3 - Article

VL - 21

SP - 1469

EP - 1476

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 9

ER -

ID: 79454394